Jazz Pharmaceuticals plc (JAZZ) · Oct 26, 2026 · Other events
$755M IPR&D charge — ~$755M pre-tax charge; approximately $11 EPS impact
Jazz Pharmaceuticals’ 8-K flags a $755M Actio acquisition charge that will cut both GAAP and adjusted Q3 EPS by about $11 before November 2 earnings.
Jazz is using acquisitions to replenish and diversify its rare-disease pipeline, with Actio adding ABS-1230, a clinical-stage epilepsy program targeting KCNT1-related disease. The Actio deal closed on September 15, 2026, so the strategic move itself was already public; this filing mainly reveals the accounting cost of bringing it onto Jazz’s books.
The new information is a very large acquisition-related accounting hit. Jazz currently estimates a roughly $755 million pre-tax acquired in-process research and development charge for the third quarter.
| Q3 2026 item | Preliminary estimate |
|---|---|
| Acquired IPR&D charge | Approximately $755 million |
| Impact on GAAP EPS | Unfavorable by approximately $11.00 |
| Impact on non-GAAP adjusted EPS | Unfavorable by approximately $11.00 |
The EPS optics are materially worse, even on Jazz’s adjusted measure. The charge is not tax deductible and is expected to reduce both GAAP EPS and non-GAAP adjusted EPS by about $11. That is unusual enough to matter because investors typically rely on adjusted EPS to look through acquisition accounting; here, Jazz says the charge will remain in that measure.
This is not an operating earnings beat or miss. Jazz has not provided finalized revenue, operating profit, cash flow, or full-quarter results in this filing; it has disclosed only a preliminary purchase-accounting charge. There is no clean published consensus for this specific IPR&D expense, so the right comparison is not “better or worse than EPS estimates,” but rather that the strategic acquisition was known while the size and adjusted-EPS treatment of the charge were not.
The underlying business story is largely unchanged for now. The filing does not indicate that ABS-1230’s clinical prospects, development timing, or commercial outlook has changed; it mainly makes the near-term reported earnings consequence of the acquisition explicit. Jazz’s next full quarterly release is scheduled for November 2, 2026.
Bottom line: This filing does not change Jazz’s pipeline strategy, but it makes the Actio acquisition look substantially more dilutive to third-quarter earnings than a normal adjusted-EPS presentation would suggest. The real operating update still comes with the November 2 results.
Q3 earnings release, November 2
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!